Paris-based company Anzen Industries, which develops cell-free enzyme technology to produce complex chemicals more efficiently and at scale, has secured $2.2 million in pre-seed funding, led by LocalGlobe and Creator Fund, to scale and relocate its operations to the US.
- Founded in 2024 by Amy Locks and Pedro Lovatt Garcia, Anzen Industries develops cell-free biomanufacturing technology aimed at producing high-value chemicals more efficiently. The company isolates and stabilizes enzymes responsible for chemical reactions, allowing these reactions to occur outside of living cells.
- Enzymes are immobilized in small, modular reactors, which enables chemical production to be scaled with lower infrastructure costs and greater control over supply chains.
- This approach addresses the limitations of traditional methods, such as plant extraction, which depends on variable harvests, and fermentation, which requires large capital investment and complex processing. By removing the dependence on whole organisms, Anzen’s technology seeks to streamline the production of complex, nature-derived molecules.
Details of the deal
- The fresh capital saw backing from LocalGlobe and Creator Fund, along with strategic angel investors from the UK, EU, and US, including Konstantin von Unger and early-stage investor Cory Levy.
- Anzen Industries will use the fresh $2.2 million funding to relocate its operations to the United States, establish its first manufacturing facility, and expand industrial collaborations and partnerships.
- Additionally, the investment will enable the company to scale its cell-free biomanufacturing platform, accelerate production of complex chemicals, and strengthen its global growth strategy.
